Text Size

Platelet Modulation: A Study of Angiogenic and Coagulation Proteins in Patients With Cancer

This study is currently recruiting participants.
Verified April 2011 by University of Vermont
Sponsor:
Information provided by:
University of Vermont
ClinicalTrials.gov Identifier:
NCT01148407
First received: June 21, 2010
Last updated: April 21, 2011
Last verified: April 2011
History of Changes
  Purpose

Blood samples on persons with cancer will be sampled for angiogenic, metastatic and coagulation proteins.


Condition
Cancer

Study Type: Observational
Official Title: Platelet Modulation in the Control of Angiogenesis: A Study of Angiogenic and Coagulation Proteins in Patients With Cancer

Resource links provided by NLM:

MedlinePlus related topics: Cancer
U.S. FDA Resources

Further study details as provided by University of Vermont:

Biospecimen Retention:   Samples Without DNA

plasma, serum and platelet activated blood samples


Estimated Enrollment: 30
Study Start Date: June 2010
Estimated Study Completion Date: August 2013
Estimated Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patients with a malignancy diagnosis.

Criteria

Inclusion Criteria:

  • Patients with a diagnosis of malignancy

Exclusion Criteria:

  • Patients taking aspirin, NSAIDs, warfarin or platelet inhibitor therapy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01148407

Contacts
Contact: Chris E Holmes, MD, PhD 802-656-0302 ceholmes@uvm.edu

Locations
United States, Vermont
University of Vermont/Fletcher Allen Health Care Recruiting
Burlington, Vermont, United States, 05401
Contact: Barbara Kelly         bkelly@uvm.edu    
Principal Investigator: Chris E Holmes, MD PhD            
Sponsors and Collaborators
University of Vermont
Investigators
Principal Investigator: Chris E Holmes, MD PhD University of Vermont
  More Information

No publications provided

Responsible Party: Chris E. Holmes, MD, PhD, University of Vermont
ClinicalTrials.gov Identifier: NCT01148407     History of Changes
Other Study ID Numbers: VCC 0806
Study First Received: June 21, 2010
Last Updated: April 21, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by University of Vermont:
breast cancer
platelets
metastatic cancer
malignancy

ClinicalTrials.gov processed this record on May 19, 2013